The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
DJ Shimza sets the record straight on trending rumors about his rapid weight loss and career perks. He denies using Ozempic, crediting exercise, diet overhaul, and supplements instead. Amid speculation, he remains open to others using GLP-1 meds like Ozempic.
At 67, Bobbi Parker-Hall microdoses Ozempic not for dramatic weight loss, but for metabolic stability and surprising intimacy benefits like multiple orgasms. She shares how low-dose semaglutide, paired with strength training, keeps her lean and vibrant post-menopause. Here's what her story reveals about this trending approach.
Demi Moore turned heads at the South By Southwest festival premiere of 'I Love Boosters!' with her strikingly slim silhouette, accentuated by a daring sleeveless wrap dress. This follows her lean look at the Actor Awards, sparking widespread online speculation about Ozempic use. While unverified, the buzz highlights growing interest in GLP-1 medications like Ozempic for weight loss.
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
GLP-1 drugs like Ozempic are silencing 'drug noise' in addicts, slashing overdoses and ER visits per a massive veterans study. Dr. Ziyad Al-Aly explains how these shots target brain reward systems. But FDA approval and insurance coverage remain years away—here's what patients need to know.
A groundbreaking study shows blockbuster drugs like Ozempic and Wegovy could be manufactured at a fraction of their retail cost, potentially revolutionizing access to obesity and diabetes care. Researchers estimate semaglutide production at $3 per month for injectables, compared to hundreds today. This comes amid rising obesity in low-income countries, though experts stress lifestyle factors remain key.
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
Influencer Brianna 'Chickenfry' LaPaglia's TikTok blast—'You're gonna die. You're all gonna die.'—targets Ozempic use among those who 'do not need' it, sparking viral debate. Page Six coverage highlights three colliding pressures amid Baptist Health's side effect warnings. Her personal recovery from disordered eating adds weight to the caution.
